Merck & Co., Inc. (MRK) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $119.96. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 7 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MRK = $187.77 (+56.5% from the current price, the stock appears undervalued). Analyst consensus target is MRK = $129 (+7.2% upside).
Valuation: MRK trades at a trailing Price-to-Earnings (P/E) of 16.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.19.
Financials: revenue is $65.0B, +3.2%/yr average growth. Net income is $18.3B, growing at +1499.6%/yr. Net profit margin is 28.1% (strong). Gross margin is 81.5% (+10.9 pp trend).
Balance sheet: total debt is $50.5B against $52.6B equity (Debt-to-Equity (D/E) ratio 0.96, moderate). Current ratio is 1.54 (strong liquidity). Debt-to-assets is 36.9%. Total assets: $136.9B.
Analyst outlook: 25 / 37 analysts rate MRK as buy (68%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 84/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 94/100 (Pass), Future 61/100 (Pass), Income 85/100 (Pass).
